Former FDA commissioner Scott Gottlieb has joined the Board of Directors for DNA sequencing specialist, Illumina.
California-based Illumina helps customers to read and understand genetic variations. The company is hoping to leverage Gottlieb's expertise to accelerate the adoption and impact of genomics into the standard of care in oncology, reproductive health and other clinical areas.
Dr. Gottlieb is currently a special partner at the venture capital firm New Enterprise Associates and a resident fellow at the American Enterprise Institute. He is currently serving on the boards of Pfizer, Aetion and FasterCures.
Read the press release